強気
$245.24
シナリオ価格
$228.490
-1.622 (-0.71%)終値時点
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
STERIS plc is a good buy right now due to its current price of $232.15, which is below the analyst price target of $275 from UBS, indicating a potential upside of 18.5%. Additionally, the company has shown a strong gross margin of 43.89% in Q4 2026, demonstrating solid profitability. The main risk is the RSI at 76.92, indicating that the stock may be overbought in the short term, but the overall fundamentals and growth outlook support a long-term investment.
UBS
$275
2026-07-28
UBS
2026-07-28
目標株価
$275
KeyBanc
$269
2026-05-13
KeyBanc
2026-05-13
目標株価
$269
Morgan Stanley
—
2026-01-08
Morgan Stanley
2026-01-08
目標株価
—
JPMorgan
—
2025-12-05
JPMorgan
2025-12-05
目標株価
—
KeyBanc
$288
2025-07-22
KeyBanc
2025-07-22
目標株価
$288
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

CooperCompanies Announces Board Leadership Changes and CEO Search

STERIS Acquires Xodus Medical for $2.1 Billion

STERIS plc Reports First Quarter Earnings Growth

Steris Reports Q1 2027 Earnings with Mixed Results

STERIS Reports Strong Q1 2027 Financial Results with Strategic Restructuring
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
STERIS plc is a good buy right now due to its current price of $232.15, which is below the analyst price target of $275 from UBS, indicating a potential upside of 18.5%. Additionally, the company has shown a strong gross margin of 43.89% in Q4 2026, demonstrating solid profitability. The main risk is the RSI at 76.92, indicating that the stock may be overbought in the short term, but the overall fundamentals and growth outlook support a long-term investment.
8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。